TY - JOUR
T1 - Structure-Activity Relationships for Inhibition of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Lung Tumorigenesis by Arylalkyl Isothiocyanates in A/J Mice
AU - Morse, Mark A.
AU - Eklind, Karin I.
AU - Hecht, Stephen S.
AU - Jordan, Kevin G.
AU - Choi, Chang In
AU - Desai, Dhimant
AU - Amin, Shantu
AU - Chung, Fung Lung
PY - 1991/4/1
Y1 - 1991/4/1
N2 - Phenethyl isothiocyanate (PEITC), 3-phenylpropyl isothiocyanate (PPITC), 4-phenylbutyl isothiocyanate (PBITC), and the newly synthesized 5-phenyIpentyl isothiocyanate (PPelTC), 6-phenyIhexyl isothiocyanate (PHITC), and 4-(3-pyridyl)butyl isothiocyanate (PyBITQ were tested for their abilities to inhibit tumorigenicity and DNA methylation induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-l-(3-pyridylH-butanone (NNK) in the lungs of A/J mice. Mice were administered isothiocyanates by gavage for 4 consecutive days at doses of 5,1, or 0.2 μmol/day prior to administration of 10 μmol of NNK by i.p. injection. Mice were sacrificed 16 weeks after NNK administration and pulmonary adenomas were quantitated. PEITC effectively inhibited NNK-induced lung tumors at a dose of 5 μmol/day but was not inhibitory at doses of 1 or 0.2 μmol/day. PPITC, PBITC, PPelTC, and PHITC were all considerably more potent inhibitors of NNK lung tumorigenesis than PEITC. While virtually no differences in inhibitory activity could be ascertained for PPITC, PBITC, and PPelTC, PHITC appeared to be the most potent tumor inhibitor of all of the compounds. At a dose of 0.2 Mmol/day, PHITC pretreatment reduced tumor multiplicity by 85%. PyBITC, an analogue of both NNK and PBITC, was ineffective as an inhibitor. Using the same protocol, the compounds were found to have qualitatively similar inhibitory effects on NNK-induced DNA methylation when administered at 1 μmol/day. These results extend our previous findings that increased alkyl chain length enhances the inhibitory activity of an arylalkyl isothiocyanate toward NNK lung tumorigenesis and demonstrate the exceptional chemopreventive potentials of two new isothiocyanates, PPelTC and PHITC.
AB - Phenethyl isothiocyanate (PEITC), 3-phenylpropyl isothiocyanate (PPITC), 4-phenylbutyl isothiocyanate (PBITC), and the newly synthesized 5-phenyIpentyl isothiocyanate (PPelTC), 6-phenyIhexyl isothiocyanate (PHITC), and 4-(3-pyridyl)butyl isothiocyanate (PyBITQ were tested for their abilities to inhibit tumorigenicity and DNA methylation induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-l-(3-pyridylH-butanone (NNK) in the lungs of A/J mice. Mice were administered isothiocyanates by gavage for 4 consecutive days at doses of 5,1, or 0.2 μmol/day prior to administration of 10 μmol of NNK by i.p. injection. Mice were sacrificed 16 weeks after NNK administration and pulmonary adenomas were quantitated. PEITC effectively inhibited NNK-induced lung tumors at a dose of 5 μmol/day but was not inhibitory at doses of 1 or 0.2 μmol/day. PPITC, PBITC, PPelTC, and PHITC were all considerably more potent inhibitors of NNK lung tumorigenesis than PEITC. While virtually no differences in inhibitory activity could be ascertained for PPITC, PBITC, and PPelTC, PHITC appeared to be the most potent tumor inhibitor of all of the compounds. At a dose of 0.2 Mmol/day, PHITC pretreatment reduced tumor multiplicity by 85%. PyBITC, an analogue of both NNK and PBITC, was ineffective as an inhibitor. Using the same protocol, the compounds were found to have qualitatively similar inhibitory effects on NNK-induced DNA methylation when administered at 1 μmol/day. These results extend our previous findings that increased alkyl chain length enhances the inhibitory activity of an arylalkyl isothiocyanate toward NNK lung tumorigenesis and demonstrate the exceptional chemopreventive potentials of two new isothiocyanates, PPelTC and PHITC.
UR - http://www.scopus.com/inward/record.url?scp=0025809376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025809376&partnerID=8YFLogxK
M3 - Article
C2 - 2004368
AN - SCOPUS:0025809376
SN - 0008-5472
VL - 51
SP - 1846
EP - 1850
JO - Cancer Research
JF - Cancer Research
IS - 7
ER -